Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study.

Heather  Gelhorn

Employment - Evidera

Sandra  Tong

No Relationships to Disclose

Grant  Maclaine

Employment - BD Biosciences; Daiichi Sankyo

Stock and Other Ownership Interests  - Ark Pharmaceuticals; BD Biosciences; Cochlear; Daiichi Sankyo; GE Healthcare (I); GlaxoSmithKline; ImpediMed; Lilly (I); Merck (I)

Consulting or Advisory Role - CryoLife

John H.  Healey

No Relationships to Disclose

Susan V.  Bukata

Honoraria - Amgen; Lilly; Merck

Consulting or Advisory Role - Amgen; Lilly; Merck

Speakers' Bureau - Lilly

Vicki Leigh  Keedy

Consulting or Advisory Role - Threshold Pharmaceuticals; ZIOPHARM Oncology

Research Funding - CytRx Corporation; eleison pharmaceuticals; Janssen; medpacto; Merrimack; pfizer; Plexxikon; Threshold Pharmaceuticals; ZIOPHARM Oncology

Stephen Patrick  Anthony

Honoraria - Spectrum Pharmaceuticals

Speakers' Bureau - Spectrum Pharmaceuticals

Travel, Accommodations, Expenses - Spectrum Pharmaceuticals

Andrew J  Wagner

Consulting or Advisory Role - Novartis; Plexxikon

Research Funding - Astex Pharmaceuticals (Inst); Genentech (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Morphotek (Inst); Novartis (Inst); Sanofi (Inst)

Daniel D.  Von Hoff

Employment - McKesson

Stock and Other Ownership Interests  - Caris Life Sciences; Cell Therapeutics; CerRx; EmergingMed; HTG, Inc.; Insys Therapeutics; McKesson; Medelis; Medical Prognosis Institute; Medtronic; SynDevRx; Targeted Genetics

Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Immunomedics; International Genomics Consortium; McKesson; Novartis; OncoMed; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology

Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Alethia Biotherapeutics; Alpha Cancer Technologies; Arsia Therapeutics; Arvinas; Azaya Therapeutics; Bellicum Pharmaceuticals; Biological Dynamics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; CanBas; Caris Life Sciences; Cavion; Cerulean Pharma; CTI; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; Halozyme; HealthCare Pharmaceuticals; Horizon Discovery; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Immunomedics; Inform Genomics; Innate Pharma; Insys Therapeutics; Invivodata; Kinex; Lilly; Lixte Biotechnology; Lorus; MBC Pharma; Medelis; MediaPharma; Medical Prognosis Institute; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Novartis; Nucana; Oncology Venture; Oncolytics; Oncolyze; OncoMed; Pain Therapeutics; Peregrine Pharmaceuticals; Pharmacyclics; Pharmatech; Pledpharma; Precision Medicine Research Associates, LLC; Puma Biotechnology; RadioRx; Reflexion Medical; RenovoRx; Samsung; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; TD2; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare

Research Funding - 3-V Biosciences (Inst); Abraxis BioScience (Inst); Agios (Inst); Bayer (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)

Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer

Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex

Arun S.  Singh

Honoraria - Biomarin

Travel, Accommodations, Expenses - Biomarin

Carlos  Becerra

Speakers' Bureau - Celgene; Lilly

Jennifer  Hanlon

Employment - Evidera

William  Lenderking

Employment - Evidera

Lindsey  Murray

Employment - Evidera

Henry H  Hsu

Stock and Other Ownership Interests  - Plexxikon

Consulting or Advisory Role - Plexxikon

Patents, Royalties, Other Intellectual Property - Plexxikon (Inst)

Paul S.  Lin

Employment - Plexxikon

Leadership - Plexxikon

Patents, Royalties, Other Intellectual Property - Plexxikon

William D.  Tap

Consulting or Advisory Role - Advaxis; Ariad; EMD Serono; Janssen; Plexxikon

Travel, Accommodations, Expenses - Boehringer Ingelheim

Other Relationship - Morphotek